Raymond James & Associates Prothena Corp Public LTD CO Transaction History

Raymond James & Associates

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2023 Oct 24, 2023	BUY	$47.3 - $70.6 $191,565 - $285,930	4,050 Added 98.37%	8,167 $394,000
Q2 2023 Jul 25, 2023	SELL	$48.26 - $78.59 $101,346 - $165,039	-2,100 Reduced 33.78%	4,117 $281,000
Q1 2023 Apr 14, 2023	BUY	$46.97 - $58.27 $56,927 - $70,623	1,212 Added 24.22%	6,217 $301,000
Q4 2022 Feb 08, 2023	BUY	$52.05 - $65.0 $260,510 - $325,325	5,005 New	5,005 $301,000
Q1 2022 May 11, 2022	SELL	$30.27 - $49.22 $142,269 - $231,334	-4,700 Closed	0 $0
Q3 2021 Nov 02, 2021	BUY	$48.2 - $78.89 $38,560 - $63,112	800 Added 20.51%	4,700 $335,000
Q2 2021 Aug 11, 2021	BUY	$21.63 - $57.65 $84,357 - $224,835	3,900 New	3,900 $200,000
Q4 2018 Feb 11, 2019	SELL	$8.73 - $13.74 $90,145 - $141,879	-10,326 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$12.7 - $15.79 $16,802 - $20,890	-1,323 Reduced 11.36%	10,326 $135,000
Q2 2018 Aug 14, 2018	BUY	$10.99 - $44.21 $128,022 - $515,002	11,649 New	11,649 $170,000

185

42.8M

162K

102K

Ticker PRTA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,922,800
Market Cap $668M
Description
Prothena Corporation plc, a late-stage clinical company, focuses on discovery and development of novel therapies for life-threatening diseases in the United States. The company is involved in developing Birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a human...

Get notified when there are updates to the investment portfolio of Raymond James & Associates, based on Form 13F filings with the SEC.

Stay updated on Raymond James & Associates with notifications on news.